Backpack Securities Lists Tokenized Moderna on Solana One Day After mRNA Cancer Vaccine Phase 3 Success

The morning after Moderna and Merck reported the first positive Phase 3 trial for an mRNA neoantigen cancer vaccine, Backpack Securities made the stock tradeable around the clock on Solana. The tokenized listing launched August 20, 2026, and accumulated $4.5 million in on-chain volume within its first 24 hours, per the @solana weekly recap published August 23.

INTerpath-001: First Phase 3 Win for a Personalized mRNA Cancer Therapy

On August 19, Moderna and Merck announced that their INTerpath-001 Phase 3 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. The trial enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma and tested intismeran autogene, Moderna and Merck's personalized mRNA neoantigen therapy developed under the mRNA-4157/V940 designation, alongside pembrolizumab (Keytruda), versus Keytruda alone.

The combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis by 59% relative to Keytruda monotherapy. INTerpath-001 is the first Phase 3 trial to demonstrate that a personalized mRNA neoantigen therapy can improve outcomes over the standard-of-care checkpoint inhibitor in an adjuvant cancer setting.

Professor Georgina Long, who helped lead the investigation, said the results mark "the first Phase 3 study to show that intismeran can reduce the risk of recurrence." Merck research chief Dr. Dean Y. Li described the readout as confirmation "of the promise of a more personalized approach."

Tokenized $MRNA Lists via Backpack Securities and Sunrise

Sunrise and Backpack Securities published the tokenized listing on Solana the following day, per the official Backpack Securities blog. Each $MRNA token is backed 1:1 by Moderna (Nasdaq: MRNA) share entitlements held within Backpack's regulated U.S. brokerage infrastructure under New York law (UCC Article 8). Holders can withdraw MRNA shares from a Backpack Securities brokerage account to convert them into on-chain tokens, and deposit those tokens back to redeem the underlying equity entitlement.

The token trades on Jupiter JUP$0.359-5.6%, Raydium RAY$2.34+3.1%, Phantom, Solflare, Kamino, Titan, and directly on Backpack Exchange.

$4.5M First-Day Volume in Context

Backpack's prior tokenized equity launches offer context. Tokenized SpaceX shares ($SPCX), Backpack's first listing in June 2026, drove the bulk of trading during Solana's record $1.04 billion tokenized equity week that followed SpaceX's Nasdaq debut. $MRNA entered with a specific catalyst those earlier listings did not have: a Phase 3 trial success announced the previous morning. Solana Compass on-chain data shows over 1,200 wallets holding $MRNA on launch day, August 20. Backpack-issued tokens account for more than 50% of weekly tokenized equity trading volume on Solana according to CryptoBriefing, despite representing only 5% of total tokenized equity supply.

Eli Lilly ($LLY) Also Lists as Healthcare Stocks Expand on Solana

Moderna was not the only pharmaceutical name added through Backpack Securities during the period. Eli Lilly shares were listed as $LLY around the same time, adding a second major drug company to the Solana tokenized equity roster.

Solana's tokenized equity supply reached an all-time high of $465 million at the time of the healthcare listings, with Solana accounting for roughly 95% of all decentralized tokenized-equity spot volume, per CryptoBriefing.

Biotech Events, Accessible Around the Clock

The sequence of events illustrates a concrete use case for on-chain equities. The INTerpath-001 announcement arrived on a weekday when Nasdaq markets were open, and Moderna shares moved during regular trading hours. By the following day, Backpack Securities had listed a Solana-native token that would allow holders to trade around any subsequent clinical update, whether an FDA accelerated approval decision, a conference presentation, or new safety data, at any hour.

Moderna had additional August catalysts beyond INTerpath-001: the company received FDA approval for mFLUSIVA, the first mRNA influenza vaccine cleared in the United States for adults 50 and older, in the same period. Both developments unfolded while a tokenized representation of MRNA was live and tradeable on Solana 24 hours a day.